In cancer management, the mCRC patients were subjected to tissue biopsy to specifically highlight RAS and BRAF mutational status (in patients with RAS wild-type) as key biomarkers to be assayed at the time of diagnosis of stage IV disease as recommended by the Current National Comprehensive Cancer Network guidelines. Here, BRAF is linked to cancer.